Journal article
Emicizumab state‐of‐the‐art update
Abstract
INTRODUCTION: Emicizumab is a bispecific monoclonal antibody developed to address the unmet needs of clotting factor replacement therapy and has become the benchmark for optimal prophylaxis in managing patients with haemophilia A with inhibitors. We describe the emicizumab rollout and pharmacokinetic strategies and their use in paediatric patients.
METHODS: The evolving real-world experience in using emicizumab has confirmed its safety, …
Authors
Mahlangu J; Iorio A; Kenet G
Journal
Haemophilia, Vol. 28, No. Suppl 4, pp. 103–110
Publisher
Wiley
Publication Date
May 2022
DOI
10.1111/hae.14524
ISSN
1351-8216